Back to News
Market Impact: 0.15
HAE Crosses Above Average Analyst Target
Source: Nasdaq
Analyst InsightsMarket Technicals & Flows
Haemonetics shares recently traded at $119.47, above the average analyst 12-month target price of $110.45. The article notes that analysts may reconsider their ratings when a stock reaches its target, but the text ends before describing any action.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
HAE0.10
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- French yields are near levels not seen since 2002. Why that could give U.S. Treasurys a boost
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- Pilot killed in attacks by Iran-backed Houthis on Riyadh airport; Saudi-led coalition vows 'firm' response
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk